Global Contract Biomanufacturing Market is expected to reach $36.6 billion by 2025; Finds New Report

The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025.

Biomanufacturing is a widely used term to describe manufacture of biologic molecules for various stages of drug development right from pre-clinical stage to commercial supply. The biologic drug manufacturing is a complex process involving huge capital and sound technical expertise. Many large and small pharmaceutical companies are turning to outsourcing the drug manufacture process to reduce capital investments on capacities and focus more on their core competencies.

Contract manufacturing organizations, particularly for R&D and clinical trials, are making product manufacture, more efficient and often less costly. In addition to that, the use of single-use bioreactors is effectively reducing the manufacture facility cost. This option is more viable for smaller and low-funded companies for their in-house candidate product manufacturing needs, whereby, the companies can avoid $50-$150 million facility costs for construction of fixed, dedicated stainless steel bioreactor-based bioprocessing systems and outsource their manufacturing requirements to CMOs which use single-use facilities which typically cost $25-$40 million for commercial manufacture.

There is a continued growth of biopharmaceutical market which is expected to nearly double in next 10 years. This will be a result of continued new product approvals, expansion of indications for current products which include less-developed countries becoming more affluent and increased drug demand of the aging population in the U.S. and other major pharmaceutical markets. Aging populations are at a high risk of developing chronic diseases such as cancer and arthritis and these diseases are being precisely targeted using biopharmaceuticals. Many blockbuster drugs losing their exclusivity are also giving room for many biosimilar (and bio-betters) companies to enter into the world’s biopharmaceuticals market subsequently attracting many CROs, CDMOs, and CMOs to enter into the picture. Hence, there is every reason to assume that future growth in biopharmaceutical outsourcing will continue at a minimum X% in western countries to about X% in Asian countries.

Now-a-days CMOs are gaining much prominence due to increased demand for the clinical and commercial supply of biologics. Such prominence is achieved mainly through capacity expansions or more easily through mergers and acquisitions. In September 2016, Asahi Glass, a Japanese manufacturer of glass, chemicals, and high-tech materials acquired a leading European bio-CMO, Biomeva Holding GmbH to expand their life science business and expand into newer geographies. Contract manufacturing services are mainly benefitting the small scale companies which lack the facilities for the biomanufacturing and also intend to not invest in fixed assets like steel bioreactors and bioprocessing facilities thus giving opportunity for the CMOs to gain market presence.

The contract biomanufacturing global market is dominated by North America which contributes to revenue of $XX billion in 2016 growing at a CAGR of X% according to IQ4I estimation. The Asia Pacific region is witnessing huge growth opportunities in terms of biologics outsourcing and many local contract manufacturing organizations are taking the lead in making this region the most sought after destination for biologics outsourcing. Some of the reasons why countries such as China and India are favourite destinations for such projects include the lower cost of labour, higher technical expertise and favourable government regulations in countries such as China. The Asia Pacific region is valued at $X billion in 2016 and is expected to grow at a strong X% CAGR from 2016-2025 reaching $X billion by 2025.

The global bio-manufacturing outsourcing market is driven by factors such as globalization of bio-manufacturing facilities, increased funding from private venture capitals and government organizations, increasing outsourcing budgets and emergence of latest technologies such as single-use bioreactors. Increased funding has been seen as a boon for Chinese CMOs for becoming a lucrative market for biomanufacturing outsourcing.

An example of such funding includes Autek Bio who raised an impressive $100 million for building Asia’s largest CMO facility in south Beijing from private and government sources. There are restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market. These include unequal distribution of biomanufacturing capacities around the globe which could pose capacity constrains in future, Stringent regulatory affairs and mandatory cGMP certifications which could make the drug manufacture process to further low down, outsourcing being restricted to only small and mid-sized companies are another major restraint where large companies are looking for CMOs as an option only when there are insufficient capabilities internally.

Spanning over 206 pages “Contract Biomanufacturing Services Global Market - Forecast to 2025” report covers Contract Biomanufacturing Global Market, Market Analysis, Contract Biomanufacturing Services, Company Profiles. This Report Covered 87 Companies Few Are - Abzena Plc, Albany Molecular Research, Inc, Asahi Glass Co. Ltd., Boehringer Ingelheim, Catalent Inc, Charles River Laboratories, Fujifilm Diosynth Biotechnologies, Horizon Discovery Group, Plc, Innovent Biologics, Jhl Biotech Inc., Lonza Group, Merck Kgaa, Patheon N.V., Proteogenix.

Please visit this link for more details: http://mrr.cm/UbZ

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare